New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:08 EDTINSYInsys backs Q2 revenue view of over $52M, consensus $52.77M
Insys Therapeutics reaffirmed its revenue guidance for Q2 ended June 30. Revenue from sales of Subsys is expected to exceed $52M for the quarter, as compared with $18.5M during 2Q13.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
08:11 EDTINSYInsys Therapeutics receives FDA ODD for LEP candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its Liposomal Encapsulated Paclitaxel, or LEP, candidate for the treatment of ovarian cancer.
January 22, 2015
11:05 EDTINSYInsys Therapeutics granted orphan status for ovarian cancer treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use